Radspherin / Oncoinvent - LARVOL DELTA

Oncoinvent ASA has launched a private placement of new shares to raise up to NOK 140 million at a fixed price of NOK 90 per share, alongside a smaller retail offering of up to the NOK equivalent of EUR 1 million through Nordnet (TipRanks) - "The company intends to use the net proceeds to extend its cash runway into the second half of 2027 and to strengthen its clinical and regulatory trajectory for Radspherin. Funding will support completion of recruitment and a more mature interim readout of the ongoing phase 2 ovarian cancer study in March or April 2027, as well as regulatory alignment with U.S. and European authorities and preparatory work for a pivotal phase 3 trial, potentially enhancing the robustness of its data and its positioning in oncology radiopharmaceuticals."

Financing • P2 data • Ovarian Cancer

Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine (Yahoo Finance) - "The publication...reports results from nine patients enrolled in the dosimetry cohorts of the Phase 1 Radspherin studies in ovarian and colorectal cancer. Positive final data from these studies, previously reported by Oncoinvent, demonstrated a favorable safety profile and encouraging efficacy signals...Results showed that absorbed radiation doses to normal organs were below levels commonly associated with risks for complications, including for organs typically regarded as activity-limiting such as the kidneys and red bone marrow."

First-in-human • P1 data • Platinum sensitive • Colorectal Cancer • Epithelial Ovarian Cancer • Ovarian Cancer

Oncoinvent…announces that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone (Cision) - "A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the highest recruitment levels achieved in the study so far....Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment."

Enrollment status • Ovarian Cancer • Peritoneal Cancer

Innovative practices in the diagnosis and treatment of peritoneal surface malignancies: insights from the 15th congress of the Peritoneal Surface Oncology Group International (PSOGI) (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi) - "The congress also highlighted the clinical significance of tumor biology and focused on emerging technologies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy and Radspherin. Furthermore, it emphasized the importance of multidisciplinary collaboration and individualized treatment, providing significant insights for the standardization and innovative development of PSM management."

Journal • Oncology

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: Oncoinvent Solutions AS | Active, not recruiting ➔ Completed | N=49 ➔ 21

Enrollment change • First-in-human • Platinum sensitive • Trial completion • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Oncoinvent secures new patent expanding protection for Radspherin (Oncoinvent Press Release) - "The newly granted patent covers a key technical development to optimize Radspherin’s performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition‑of‑matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide....Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026."

P2 data • Patent • Colorectal Cancer • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Ovarian Cancer • Peritoneal Cancer

RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Oncoinvent AS

New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Oncoinvent AS | Trial completion date: Feb 2023 ➔ Oct 2023 | Trial primary completion date: Jan 2021 ➔ Dec 2022

First-in-human • Platinum sensitive • Trial completion date • Trial primary completion date • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Oncoinvent AS | Trial completion date: Feb 2022 ➔ Jan 2023 | Initiation date: Feb 2019 ➔ Dec 2019

Trial completion date • Trial initiation date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Oncoinvent AS | Trial primary completion date: Dec 2020 ➔ Dec 2022

Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Oncoinvent AS | Trial completion date: Jun 2022 ➔ Feb 2023 | Initiation date: Feb 2019 ➔ Dec 2019

First-in-human • Platinum sensitive • Trial completion date • Trial initiation date • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Oncoinvent AS | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Oncoinvent AS

First-in-human • New P1 trial • Platinum sensitive • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov) - P1/2 | N=67 | Active, not recruiting | Sponsor: Oncoinvent AS | Recruiting ➔ Active, not recruiting

Enrollment closed • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=49 | Active, not recruiting | Sponsor: Oncoinvent AS | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Platinum sensitive • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov) - P1/2 | N=67 | Recruiting | Sponsor: Oncoinvent AS | Phase classification: P1 ➔ P1/2 | N=39 ➔ 67 | Trial completion date: Mar 2023 ➔ Feb 2025 | Trial primary completion date: Dec 2022 ➔ Feb 2025

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=49 | Recruiting | Sponsor: Oncoinvent AS | N=33 ➔ 49 | Trial completion date: Oct 2023 ➔ Aug 2025 | Trial primary completion date: Dec 2022 ➔ Aug 2025

Enrollment change • First-in-human • Platinum sensitive • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: Oncoinvent AS | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Platinum sensitive • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Safety and efficacy results from a phase 1 study of intraperitoneal alpha-emitting radium-224 labelled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer (ESGO 2026) - "No grade ≥3 adverse events deemed related to Radspherin. At 24-months, only 1 of the 10 patients treated with the recommended dose experienced peritoneal recurrence, encouraging for the ongoing Phase 2 study at interval debulking surgery during first-line chemotherapy in ovarian cancer."

Clinical • P1 data • Platinum sensitive • Surgery • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Oncoinvent...announced that it will present final 24‑month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. (Oncoinvent Press Release) - "21 patients enrolled across dose levels with a favourable safety profile and no dose‑limiting toxicities observed; No grade ≥3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence."

P1 data • Platinum sensitive • Epithelial Ovarian Cancer • Ovarian Cancer

Experiences and Hopes Among Patients with Colorectal Carcinoma and Peritoneal Metastases Who Are Participating in an Early-Phase Clinical Trial. (PubMed, Cancers (Basel)) - "Background: Radspherin® is a novel α-emitting radiopharmaceutical administered intraperitoneally following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for peritoneal metastases...Their willingness to participate in experimental treatment was shaped by trust in clinicians, clear communication, and a desire for extended survival. However, the burden of CRS-HIPEC-related side effects underscores the importance of tailored follow-up and support."

Journal • Colorectal Cancer • Fatigue • Oncology • Pain • Solid Tumor

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin to Treat Ovarian Cancer (Oncoinvent Press Release) - "In this Phase 1 trial, 10 out of 21 patients received the highest and recommended intraperitoneal dose of 7 MBq Radspherin after dose escalation (1, 2, 4 and 7 MBq).The final 24-month data still reports that only 1 of these 10 patients had peritoneal recurrence, and peritoneal recurrence rate remains at 10%. Two additional patients were reported with lymph node metastases outside of the peritoneum, giving an overall recurrence rate of 30%. In similar populations, approximately 55-60% of patients receiving best standard of care would expect disease recurrence at this time point."

P1 data • Platinum resistant • Ovarian Cancer • Peritoneal Cancer

First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer. (PubMed, Gynecol Oncol) - P1 | "All dose levels were well tolerated, with no DLT observed. The highest activity dose of 7 MBq was selected as recommended dose for an expansion cohort. No grade ≥ 3 adverse events related to Radspherin were reported."

Journal • Platinum sensitive • Epithelial Ovarian Cancer • Hematological Disorders • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies (Oncoinvent Press Release) - "The final 18-month data reported that only 10 of these 36 patients (27.8 %) had peritoneal recurrence. Remarkably, only 2 out of the 36 patients experienced peritoneal metastases as the only site of disease recurrence. Further, at 18 months 61.1% (22 of 36) patients had experienced new metastases overall, giving a median disease-free survival of 13.5 months....The results strengthen the potential for Radspherin as a novel treatment option for patients with peritoneal metastases from colorectal cancer, demonstrating both clinical promise, as well as being well tolerated and safe to use..."

P1/2 data • Colorectal Cancer

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin to Treat Ovarian Cancer (PRNewswire) - "The final 24-month data still reports that only 1 of these 10 patients had peritoneal recurrence, and peritoneal recurrence rate remains at 10%. Two additional patients were reported with lymph node metastases outside of the peritoneum, giving an overall recurrence rate of 30%....'We...look forward to interim results from our Phase 2 study next year'."

Clinical data • Platinum sensitive • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Peritoneal Cancer